650 results about "Atopic dermatitis" patented technology

To provide a pharmaceutical agent that has STAT6 inhibitory activity and is effective for the treatment of allergic diseases and inflammatory diseases such as atopic dermatitis.SOLUTION: A pharmaceutical agent contains, as an active ingredient, a compound represented by the general formula (I) in the figure or a pharmaceutically acceptable salt thereof, which has STAT6 inhibitory activity.SELECTED DRAWING: None

The invention relates to a novel application of animal bifidobacterium subsp. Lactis BGI-N3, in particular to an application of the animal bifidobacterium subsp. Lactis BGI-N3 in preparation of a preparation for relieving skin allergy. The invention finds that the bifidobacterium animalis subsp. Lactis BGI-N3 has a very remarkable effect in the aspect of relieving skin allergy, and the effect is specifically shown as follows: in an atopic dermatitis animal model, the dermatitis score, scratching times and percutaneous water loss are remarkably reduced, and the atopic dermatitis skin tissue damage condition is relieved; the immune organ edema condition is improved, the levels of Th2 type cell factors and inflammatory factors IL-6, TNF-alpha and IFN-gamma related to dermatitis are reduced, and the immune balance of the body is recovered; expression of fibroin and endothelial protein in skin tissue is improved, and the skin barrier is repaired; the level of antibacterial peptide in skin tissues is recovered, and the antibacterial activity of the skin is enhanced. Meanwhile, compared with a traditional chemical medicine for treating atopic dermatitis, the animal bifidobacterium subsp. Lactis BGI-N3 has no side effects such as weight loss, immune organ atrophy, immune imbalance and the like.

The invention relates to the technical field of microorganisms, in particular to a bifidobacterium animalis subsp. Lactis and application thereof, and particularly provides a bifidobacterium animalis subsp. Lactis BX-BC08 which is beneficial for restoring the microecological balance of the intestinal tract and enhancing the immune barrier function of the intestinal tract. Experiments prove that the bifidobacterium animalis subsp. Lactis BX-BC08 disclosed by the invention can regulate an immune system and relieve excessive immune response, can reduce generation of inflammatory factors and relieve skin inflammation symptoms for autoimmune related diseases such as atopic dermatitis, is relatively good in tolerance to a human body, and greatly reduces adverse reaction of the human body.

Pet food compositions, and particularly, pet food compositions comprising fish collagen hydrolysate are disclosed herein. Also disclosed herein are methods of treating an immune disorder, such as atopic dermatitis in a companion animal in need thereof and methods of alleviating at least one of pruritus, erythema, or alopecia in a companion animal with atopic dermatitis.

The invention relates to the technical field of biological medicine, and particularly discloses an atopic dermatitis treatment medicine and a preparation method and application thereof.The preparation method comprises the steps that sodium alginate, sodium polyacrylate and water are mixed and then subjected to a swelling reaction, and a colloidal solution with the viscosity larger than or equal to 5000 cP is formed; mixing upatinib, a preservative, glycerol and azone to obtain a raw material phase; and mixing the colloidal solution with the raw materials, and homogenizing to obtain the atopic dermatitis treatment medicine. Through swelling reaction of sodium alginate and sodium polyacrylate, the viscosity of a colloidal solution is remarkably improved through molecular chain entanglement, charge repulsion and water absorption synergistic effects of sodium alginate and sodium polyacrylate; through compounding of all the components, the transdermal efficiency of the medicine is improved, the irritation of the medicine is reduced, and meanwhile, the inhibition efficiency on atopic dermatitis inflammatory factors is also improved.

Aspects of the application provide bispecific antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis. In some embodiments, the bispecific antibody comprises at least one antigen-specific binding site that specifically binds KLK5 and KLK7 and at least one antigen-specific binding site that specifically binds to a Th2 cytokine (e.g., IL-13) or receptor thereof.

The invention discloses a novel application of bifidobacterium longum subsp. Infantis CCFM1269 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. Infantis CCFM1269 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mast cell infiltration is reduced; (2) reducing the total IgE level of serum; (3) the Treg level of mesenteric lymph nodes and the ILA content of serum are improved; (4) IL-4 and TSLP levels in skin tissues are reduced, IL-10 is improved, and Th1 / Th2 immune balance is recovered; (5) improving AHR and CYP1A1 in the skin tissue; and (4) high yield of ILA.

Methods for treating itch in human patients with atopic dermatitis (AD) and / or prurigo nodularis (PN) comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3- yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

The invention discloses bifidobacterium breve BBr26 capable of inhibiting hyaluronidase activity and relieving allergy as well as an application, a product and a method of the bifidobacterium breve BBr26, and belongs to the technical field of microorganisms. The invention provides a Bifidobacterium breve (Bifidobacterium breve) strain BBr26 with anti-allergy and / or immunoregulation capability, and the preservation number of the Bifidobacterium breve strain BBr26 is CGMCC (China General Microbiological Culture Collection Center) NO.32424. The invention also provides a preparation method of the Bifidobacterium breve strain The invention also provides an application of the strain bifidobacterium breve BBr26 in preparation of products for relieving atopic dermatitis, and / or food for enhancing immune function, and / or bacteriostatic agents, and a product and a method based on the strain BBr26. The strain disclosed by the invention has broad-spectrum bacteriostasis, can relieve allergy and atopic dermatitis, and can effectively play a role in immunoregulation.

The invention discloses application of a zingiber mioga extract in preparation of a medicine for treating atopic dermatitis, and belongs to the technical field of medicines.The zingiber mioga extract is specifically a zingiber mioga rhizome aqueous extract, can act on all stages of atopic dermatitis to achieve the purposes of relieving inflammation and improving itching symptoms, has higher safety and effectiveness, and can be used for preparing a medicine for treating atopic dermatitis. Therefore, the traditional Chinese medicine composition has great potential and unique advantages in the aspect of treating atopic dermatitis. The invention provides a new thought for developing the atopic dermatitis medicine, and also expands the application direction of the zingiber mioga.

The invention belongs to the technical field of new application of medicines, and particularly relates to application of ganoderan GLP-2 in preparation of a medicine for improving atopic dermatitis. The structural formula of the ganoderma lucidum polysaccharide GLP-2 is as follows: # imgabs0 #, wherein m is equal to 10; n = 7. The research on the action mechanism of the ganoderan on mice with atopic dermatitis is discussed, theoretical guidance and practical experience are provided for further research of the ganoderan and products thereof, and the method has important theoretical value and application value.

The present invention relates to anti-canine IL-4Rα monoclonal antibodies of high potency regarding inhibition of IL-4Rα signaling pathway, and the use thereof for treating and / or preventing itch and / or inflammatory skin due to atopic dermatitis and allergies in dogs, and in particular for treating canine atopic dermatitis.

The invention provides a probiotic composition as well as a preparation method and application thereof. The composition is prepared from lactobacillus rhamnosus GG, lactobacillus acidophilus NCFM, an anti-IL-4R alpha monoclonal antibody, an inulin-beta-glucan compound and sodium alginate-chitosan microspheres. The composition regulates immune balance through a specific probiotic strain, blocks an IL-4 / IL-13 signal channel in combination with an anti-IL-4R alpha monoclonal antibody, and improves viable bacterium stability and bioavailability through a microsphere delivery technology. The probiotic composition shows a remarkable anti-allergic effect in an atopic dermatitis mouse model, and can reduce the serum IgE level, reduce the skin inflammatory response and reduce the STAT6 phosphorylation level. The probiotic composition disclosed by the invention has a wide application prospect in the aspect of treating atopic dermatitis and other immune-related diseases.

The present invention provides the use of a toad oil cream in preparing a drug for treating dermatitis, and relates to the field of medical technology. The toad oil cream is composed of toad oil and a matrix, and the toad oil is prepared according to the method of Chinese invention patent application CN117126696 A, and the matrix is ​​composed of cetostearyl alcohol, glyceryl monostearate, liquid paraffin, dimethicone, propylparaben, carbomer, glycerol, potassium lauryl phosphate, hyaluronic acid, methylparaben, triethanolamine and water. The toad oil cream obtained by the present invention can reduce the irritation of toad oil to the skin, improve the spreadability of toad oil, show good therapeutic effects on atopic dermatitis and contact dermatitis, and can be used to treat dermatitis.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The present invention relates to the field of biomedicine. Provided are an anti-human IL-4Rα antibody or an antigen-binding fragment thereof and the use thereof. The anti-human IL-4Rα antibody comprises heavy chain complementarity determination regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determination regions LCDR1, LCDR2 and LCDR3, has high affinity with human IL-4Rα, can be used for preparing an antibody drug, can be used for treating type-II inflammatory diseases, and has relatively good clinical efficacy and relatively low toxic and side effects. Further provided are a bispecific antibody against both IL-4Rα and TSLP, and the use of the antibody in the preparation of a drug for treating severe asthma, moderate to severe atopic dermatitis and chronic obstructive pulmonary disease.

The present invention relates to a composition for treating atopic dermatitis, the composition comprising stichopus japonicus-derived extracellular vesicles. Treating LPS-induced inflammation macrophages and mouse models with stichopus japonicus-derived extracellular vesicles was found to activate anti-inflammatory effects. Accordingly, the composition comprising stichopus japonicus-derived extracellular vesicles has an excellent therapeutic effect on atopic dermatitis and can be utilized in the field of researching better therapeutic effects, and thus can be used in useful businesses related to atopic dermatitis.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

Provided are a method for preparing a protein marker for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization in infants, and a method for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization using said protein marker.　More specifically, the method for preparing a protein marker for predicting the risk of developing atopic dermatitis includes recovering at least one kind of protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2 and PRG2 from a sample collected from the skin of an infant subject.

The invention relates to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating atopic dermatitis. The traditional Chinese medicine composition contains cynanchum paniculatum, tripterygium wilfordii, bletilla striata, cuttlebone, duckweed, mint, radix sophorae flavescentis, golden cypress, moutan bark and liquorice. In addition, the invention further provides a traditional Chinese medicine preparation for treating atopic dermatitis and a preparation method and application of the traditional Chinese medicine preparation. The traditional Chinese medicine composition has the effects of dispelling wind, relieving itching, astringing to stop bleeding, clearing heat, drying dampness, detoxifying and dredging collaterals, and has no toxic or side effect.

The invention discloses an extracellular vesicle derived from rhodomonas mucilaginosa and a hydrogel composition of the extracellular vesicle. The extracellular vesicle is obtained by carrying out ultrafiltration concentration and gradient ultracentrifugation on a culture bacterium solution. Compared with an original culture solution or a viable bacterium preparation thereof, the treatment efficiency and the safety of the extracellular vesicles are remarkably improved. Based on the extracellular vesicle, the invention also provides a hydrogel composition loaded with the extracellular vesicle, and the hydrogel composition is constructed from the extracellular vesicle, type I collagen, carboxymethyl chitosan and four-arm polyethylene glycol benzaldehyde in a chemical crosslinking manner, and has good adhesiveness, self-repairing ability and injectability. The extracellular vesicle, the hydrogel composition and the hydrogel preparation of the extracellular vesicle can serve as a medicine or a medicine carrier to be applied to atopic dermatitis, can specifically target 2-type inflammatory factors, and relieve pathological changes such as skin lesion phenotype, epidermis thickening, mast cell infiltration and inflammatory factor expression increase of an MC903-induced atopic dermatitis mouse model.

The present disclosure provides multi-domain molecules comprising, (i) a first binding domain that binds to PD-1, (ii) a second binding domain that binds to CD1a, and optionally, (iii) a half-life extending domain. Such multi-domain molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as atopic dermatitis (AD).

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The invention discloses an application of glucopyranose sulfate galactooligosacharide in preparation of a medicine for treating atopic dermatitis. The glucopyranose galactooligosaccharide can significantly improve the skin condition of a DNCB-induced atopic dermatitis mouse model, including reducing the skin inflammatory factor level, improving the skin barrier function, and reducing the lymph node quality and the number of lymphocytes, and has no abnormal influence on blood routine. The composition has the advantages of small drug application dosage, low pharmaceutical cost, safety, no side effect, strong drug effect and the like, and has a wide application prospect.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The present application relates to an NEK7 inhibitor, a pharmaceutical composition and a use thereof. The compound has a structural formula of formula (I). The compound of the present disclosure has good NEK7 inhibitory activity, and can be used for treating or preventing inflammatory pathological disorders (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout, etc.) regulated by the NLRP3 inflammasome.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The invention discloses a hydrogel dressing for treating atopic dermatitis and a preparation method and application thereof, and belongs to the technical field of skin medical materials. The dressing is prepared by taking a glycerol / water / ethanol ternary mixed solvent as a dissolving system, dissolving polyvinyl alcohol, tannic acid and aluminum trichloride to construct a polymer skeleton matrix, and then adding traditional Chinese medicine active ingredients. The preparation does not need complex temperature control curing, the ternary solvent can realize uniform dissolution and stable dispersion of the active ingredients, the effective ingredients are prevented from being damaged by high temperature, the encapsulation efficiency of the traditional Chinese medicine extract is more than 90%, and the medicine can be slowly released for 72 hours. The dressing has a multi-target anti-inflammatory effect, can reduce the level of TNF-alpha at a skin lesion and promote proliferation of keratinocytes, is excellent in tensile and torsional stability, and can be attached to the skin for a long time in a dynamic environment. The preparation method is simple in process, controllable in raw material cost, high in production efficiency, suitable for large-scale production, good in dressing biocompatibility, high in safety, suitable for treatment of atopic dermatitis of different severity degrees and large in clinical transformation potential.

Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.